Mendota Financial Group LLC Has $155,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Mendota Financial Group LLC reduced its holdings in AstraZeneca PLC (NASDAQ:AZN) by 10.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,989 shares of the company’s stock after selling 235 shares during the period. Mendota Financial Group LLC’s holdings in AstraZeneca were worth $155,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GHP Investment Advisors Inc. acquired a new position in AstraZeneca in the 2nd quarter valued at approximately $26,000. Able Wealth Management LLC bought a new stake in AstraZeneca in the 4th quarter valued at $27,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at $29,000. Hobbs Group Advisors LLC bought a new position in shares of AstraZeneca during the 2nd quarter worth about $35,000. Finally, Versant Capital Management Inc boosted its position in shares of AstraZeneca by 1,614.8% during the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after acquiring an additional 436 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. TD Cowen raised their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $77.35 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The stock has a market capitalization of $239.83 billion, a P/E ratio of 37.37, a P/E/G ratio of 1.42 and a beta of 0.46. The business has a 50-day moving average price of $81.36 and a two-hundred day moving average price of $77.75.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the firm posted $1.08 earnings per share. AstraZeneca’s revenue for the quarter was up 9.1% compared to the same quarter last year. Equities analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were given a $0.49 dividend. The ex-dividend date was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is currently 47.34%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.